Oruka Therapeutics Inc. Common Stock vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $25.29 (market cap $159.50M). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 32.5× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Roundhill Russell 2000 0DTE Covered Call Strat ETF for 56 Days on average.
| ORKA | RDTE | |
|---|---|---|
Market Cap | $5.18B | $159.50M |
Volume | 490,798 | 55,754 |
Sector | Health | Income / Options Overlay |
52-Week High | $113.08 | $33.66 |
52-Week Low | $26.19 | $25.43 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $4.31B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RDTE (Roundhill Russell 2000 0DTE Covered Call Strategy ETF) trades at $25.91, down 0.54% with bearish technical indicators showing 17 sell signals versus 0 buy signals. The ETF faces capital erosion concerns despite offering high dividend yields through its covered call strategy on Russell 2000 small-cap stocks. Recent dividend payments have ranged from $0.10 to $0.23 per share, but the fund's income generation comes with significant price depreciation risk.
The outlook remains challenging as technical analysis indicates strong bearish momentum with moving averages unanimously signaling sell. Fundamental data is limited but the covered call strategy exposes investors to capped upside potential during market rallies while providing limited downside protection. Key risks include small-cap volatility and the structural limitations of 0DTE options strategies in generating sustainable income.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →